Kainos Medicine Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Investments
  • 2

  • Share Price
  • $16.44
  • (As of Thursday Closing)

Kainos Medicine General Information

Description

Developer of novel drugs intended to provide research and develop various medicines for cancers and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is under phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under phase II clinical study to treat HIV/AIDS, thereby providing healthcare companies and healthcare professionals with the various treatment for novel diseases such as brain diseases and cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3F, Building. A, Korea Bio-Park, 700 Daewangpangyo-ro
  • Bundang-gu, Gyeonggi-do
  • Seongnam-si, 13488
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3F, Building. A, Korea Bio-Park, 700 Daewangpangyo-ro
  • Bundang-gu, Gyeonggi-do
  • Seongnam-si, 13488
  • South Korea
+82

Kainos Medicine Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kainos Medicine Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.44 $16.29 $9.10 - $19.02 $231M 14.1M 36K -$0.49

Kainos Medicine Financials Summary

In Thousands,
USD
TTM 31-Dec-2019 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 189,988 189,988 161,753 80,738
Revenue 1,921
EBITDA (6,494) (6,494) (7,061) (2,091)
Net Income (6,805) (6,805) (7,228) (2,314)
Total Assets 4,747 4,747 7,323 7,100
Total Debt 179 179 0 66
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kainos Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kainos Medicine‘s full profile, request access.

Request a free trial

Kainos Medicine Patents

Kainos Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4444716-A1 Compositions and methods for treating cancer Pending 06-Dec-2021
CA-3215574-A1 Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent Pending 30-Mar-2021
AU-2022247243-A1 Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent Pending 30-Mar-2021
JP-2024512691-A Fas-associated factor 1 (faf1)-containing exosomes and their use as anticancer agents Pending 30-Mar-2021
EP-4316467-A1 Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent Pending 30-Mar-2021 A61K38/1761
To view Kainos Medicine’s complete patent history, request access »

Kainos Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kainos Medicine Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kainos Medicine‘s full profile, request access.

Request a free trial

Kainos Medicine Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
FAScinate Therapeutics 01-Aug-2020 Drug Discovery
Hana Financial Eleventh Special Purpose Acquisition 08-Jun-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Kainos Medicine’s complete investments and acquisitions history, request access »

Kainos Medicine FAQs

  • When was Kainos Medicine founded?

    Kainos Medicine was founded in 2007.

  • Where is Kainos Medicine headquartered?

    Kainos Medicine is headquartered in Seongnam-si, South Korea.

  • What is the size of Kainos Medicine?

    Kainos Medicine has 25 total employees.

  • What industry is Kainos Medicine in?

    Kainos Medicine’s primary industry is Drug Discovery.

  • Is Kainos Medicine a private or public company?

    Kainos Medicine is a Public company.

  • What is the current stock price of Kainos Medicine?

    As of 14-May-2020 the stock price of Kainos Medicine is $16.44.

  • What is the current market cap of Kainos Medicine?

    The current market capitalization of Kainos Medicine is $231M.

  • What is Kainos Medicine’s annual earnings per share (EPS)?

    Kainos Medicine’s EPS for 12 months was -$0.49.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »